June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
The Effect of Topical Prostaglandins on Migraine Headaches
Author Affiliations & Notes
  • Laura Hall
    Yale Eye Center, Yale University School of Medicine, New Haven, Connecticut, United States
  • Venkatesh Brahma
    Yale Eye Center, Yale University School of Medicine, New Haven, Connecticut, United States
  • Robert L. Lesser
    Neuro-ophthalmology, The Eye Care Group, New Haven, Connecticut, United States
  • Adeniyi Fisayo
    Yale Eye Center, Yale University School of Medicine, New Haven, Connecticut, United States
  • Martin Wand
    Consulting Ophthalmologists, PC, Farmington, Connecticut, United States
  • Christopher Teng
    Yale Eye Center, Yale University School of Medicine, New Haven, Connecticut, United States
  • Footnotes
    Commercial Relationships   Laura Hall, None; Venkatesh Brahma, None; Robert Lesser, None; Adeniyi Fisayo, None; Martin Wand, Patent: WO 2015 10606; Company: Manistee Partners (P); Christopher Teng, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 5131. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Laura Hall, Venkatesh Brahma, Robert L. Lesser, Adeniyi Fisayo, Martin Wand, Christopher Teng; The Effect of Topical Prostaglandins on Migraine Headaches. Invest. Ophthalmol. Vis. Sci. 2017;58(8):5131.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Migraine headaches are a major health burden and cause of disability. Many suffer without adequate short-term treatment and/or long-term control. We observed that treatment with topical prostaglandin analogues decreased the frequency, severity and duration of migraines. We surveyed patients about their migraine symptoms before and after treatment to learn about the changes potentially related prostaglandin use.

Methods : We conducted retrospective surveys on 12 patients (4 males, overall average age 58.2 years). Participants were migraine sufferers treated with prostaglandin analogues either in their eyes (1 drop in both eyes as indicated for the treatment of elevated intraocular pressure) or on the fingernail bed (1 drop applied nightly to the lunula of four to six nails and allowed to dry). We collected data on their migraine history and symptoms before and after treatment with prostaglandins using expanded Migraine Disability Assessment (MIDAS) questionnaires. The Wilcoxon Signed-Rank Test was used to calculate the change in migraine frequency, severity, duration and modified MIDAS scores with prostaglandin treatment.

Results : Two subjects used prostaglandin eye drops in their eyes (average length of treatment 79.5 months) and 9 subjects used them on their nails (average length of treatment 8.2 months). There was a decrease in the number of headache days from the 3-month period before treatment (mean 25.8 headache days) to the 3-month period following treatment (mean 7.7 headache days) (p≤ 0.05). There was also a decrease in headache severity from 5.8 to 3.5 (scale of 0-10) (p≤ 0.05) and headache duration from 3-12 hours to 1-3 hours (p≤ 0.05). The MIDAS score also reduced from 18.4 to 2.8 (p≤ 0.05). No adverse effects were reported with fingernail application however it was noted that fingernail growth accelerated.

Conclusions : Prostaglandin analogues are FDA approved for the treatment of elevated intraocular pressure applied to the eye. When used in patients with migraine headaches, there was improvement in the frequency, duration and severity of migraine headaches. Prostaglandin analogues could prove to be a novel treatment modality for the management of migraine headaches.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×